Search PubMed⌕ Search

Biomedical subjects

G Lupo

Publications and source records attributed to G Lupo.

At least 55 records · Page 3Linked to original sources
PubMed1987

AIDS in Sicily: prevalence of antibodies to human immunodeficiency virus (HIV) in low and high risk groups.

A seroepidemiological survey, carried out to evaluate the prevalence of antibodies to HIV in patients with ARC and in healthy individuals at risk for AIDS, showed the infection to be widespread in the groups at risk, namely in drug abusers and hemophiliacs. However, remarkable difference existed between the prevalence of antibodies to HIV in drug abusers of the city of Palermo and those of other Sicilian provinces. Spread of the virus among Sicilian thalassemics, however, was very low and quite similar in all geographic areas. Antibodies were found very rarely (0.06%) in unpaid voluntary blood donors. The spread of the virus is still confined in high risk groups, and the major part of the seropositive blood donors were identified a posteriori as drug abusers.

AIDS-Related Complex↗
PubMed1987

Long term results in cleft and palate repair with modified periosteal flap technique.

The authors describe their multidisciplinary approach to cleft lip and palate repair. The preoperative treatment is performed only in a few selected cases. The lip is operated on at 3 months of age with a periosteal flap, slightly modifying Skoog's technique. The cleft palate is closed at 18 months (Langenbeck method). The orthodontic treatment is undertaken at 6 or 7 years. 45 cases are periodically investigated (casts, masks, X-ray, cephalograms, records, films). Our follow-up covers a range of 9 years. Results are satisfactory.

Alveoloplasty↗
PubMed1987

Choice of techniques in nasal repairs.

The authors after classifying skin loss of the nose according to their size and site, resume the techniques they normally use in every kind of loss. They suggest those most reliable and easy to perform.

Humans↗
PubMed1984

Evolving concepts in lip reconstruction.

An extensive review of world literature reveals that current innumerable procedures to repair upper and lower lip defects were already devised about the middle of the nineteenth century. There is little that can be defined as original after that time. In fact, most of the so-called new methods for labial reconstruction are a modification of old ideas. In tracing the steps of evolution in lip repair, the authors emphasize that only few concepts should be regarded as decisive to achieve a good final result. The use of lip tissue to repair lip defects should be one of the aims of modern cheiloplasty. Following this principle, it is possible to reestablish interrupted sphincteric functions of the orbicularis oris and, at the same time, most of the expression of emotions. When insufficient material is available for reconstruction, full-thickness local flaps of cheek can be considered the alternative solution, far better than distant lined flaps, which create a static, unaesthetic barrier.

Cleft Lip↗
PubMed1984

Our experience with lip reconstruction. A lesson from history.

The authors' philosophy in performing labial reconstruction has evolved from unsatisfactory results using classic procedures. Such results prompted attempts with procedures that are both more cosmetic and functional and that give greater emphasis to the restoration of the oral sphincter.

Adult↗
PubMedDate not supplied

The history of aesthetic rhinoplasty: special emphasis on the saddle nose.

The author, after a brief review of the main ideal size, proportion, and units of measurement of the nose, describes the historical techniques employed for cosmetic rhinoplasty. Particular attention is given to Sanvenero-Rosselli's cases. A paragraph is reserved for the history regarding the correction of saddle-nose and the main materials employed for the correction (autografts, allografts, xenografts, and implants). For each procedure, they were mentioned the first time they were employed.

History, 15th Century↗
PubMedDate not supplied

Gemcitabine as single agent in the treatment of elderly patients with advanced non small cell lung cancer.

BACKGROUND: In phase II trials gemicitabine proved to be an active agent in NSCLC, producing a clinical benefit, often higher than response rate. PATIENTS AND METHODS: We assessed the impact of gemcitabine treatment on response rate and quality of life in 21 untreated elderly patients (aged > 70 years) with NSCLC. Gemcitabine (1250 mg/sm) was administered days 1-8 every 21 days. Response and toxicity were analyzed according to WHO criteria. The assessment of quality of life was performed by analysing a disease symptom related questionnaire completed by the patient. RESULTS: All the patients were evaluable: we found 7 PR (33%), 5 SD (24%) and 9 PD; the median duration of response was 24 weeks; the median overall survival 32 weeks; WHO grade 2 leukopenia (in 4 patients) and thrombocytopenia (grade 3 in 1 patient and grade 2 in two patients) were the main toxic effects. A clinical benefit was demonstrated in all 12 patients with PR or SD and in 3 patients with PD. CONCLUSIONS: These data confirm that gemcitabine is a well tolerated and active therapeutic approach in elderly non small cell lung cancer patients.

Adenocarcinoma↗